No Supra Additive Effects Of Goserelin And Radiotherapy On Clonogenic Survival Of Prostate Carcinoma Cells

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Endocrinology;  Men's health
Article Date: 12 Oct 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

UroToday.com - Luteinising hormone releasing hormone (LHRH) analogs improve survival rates when applied during curative radiotherapy for prostate cancer (PC). However, the mechanism of this enhancement of radiosensitivity of tumor cells is still obscure. As about 85% of PC express LHRH receptors, we postulated a direct interaction between LHRH agonists and radiotherapy in the tumor cells.

However, in this study we could exclude any interaction of both treatment modalities in LNCaP and PC-3 cells. Proliferation or clonogenic survival was not influenced after irradiaton by exposure to LHRH-analog. The clinically observed increase in tumor control after combination of goserelin with radiotherapy in PC must be attributed to synergistic effects of androgen deprivation and irradiation.

Written by R.M. Hermann, MD, as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------

• Additional
• References
• Citations